Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 20, Issue 40, Pages 14821
Publisher
Baishideng Publishing Group Inc.
Online
2014-10-28
DOI
10.3748/wjg.v20.i40.14821
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women
- (2014) A. de Souza Bruno et al. CLIMACTERIC
- Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation
- (2013) Yao Dai et al. CARDIOVASCULAR DRUGS AND THERAPY
- Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients
- (2013) N. D. Hopkins et al. DIABETES OBESITY & METABOLISM
- Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents
- (2013) Hui Chen et al. DIABETOLOGIA
- A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes
- (2013) Justin J. Wilkins et al. JOURNAL OF CLINICAL PHARMACOLOGY
- GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK
- (2013) Lili Zhang et al. LIVER INTERNATIONAL
- Acute peripheral administration of synthetic human GLP-1 (7–36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?
- (2013) Christina Daousi et al. REGULATORY PEPTIDES
- The Effect of Glucagon-Like Peptide-1 Receptor Agonist Therapy on Body Mass Index in Adolescents With Severe Obesity
- (2013) Aaron S. Kelly et al. JAMA Pediatrics
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Glucagon-Like Peptide-1 Receptor Agonist Exendin 4 Has a Protective Role in Ischemic Injury of Lean and Steatotic Liver by Inhibiting Cell Death and Stimulating Lipolysis
- (2012) Nitika A. Gupta et al. AMERICAN JOURNAL OF PATHOLOGY
- Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression
- (2012) Ayako Ojima et al. AMERICAN JOURNAL OF PATHOLOGY
- The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells
- (2012) Aya Shiraki et al. ATHEROSCLEROSIS
- Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity
- (2012) Chun-jun Li et al. Cardiovascular Diabetology
- Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
- (2012) Aaron S Kelly et al. Cardiovascular Diabetology
- Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks
- (2012) R. M. Bergenstal et al. DIABETES OBESITY & METABOLISM
- Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes
- (2012) G. Derosa et al. DIABETIC MEDICINE
- Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes
- (2012) Y.-S. Lee et al. DIABETOLOGIA
- The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain
- (2012) Vadivel Parthsarathy et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury
- (2012) Yoichiro Hirata et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression
- (2012) Yuli Cai et al. MOLECULAR BIOLOGY REPORTS
- Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- (2012) Daniel J. Cuthbertson et al. PLoS One
- The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
- (2012) Takamasa Ohki et al. TheScientificWorldJOURNAL
- Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care
- (2012) K. Khunti et al. BMJ-British Medical Journal
- Exendin-4 upregulates the expression of Wnt-4, a novel regulator of pancreatic β-cell proliferation
- (2011) Charlotte Heller et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes
- (2011) Kana Inoue et al. Cardiovascular Diabetology
- NF-κB, Inflammation, and Metabolic Disease
- (2011) Rebecca G. Baker et al. Cell Metabolism
- Evaluating Treatment Algorithms for the Management of Patients With Type 2 Diabetes Mellitus: A Perspective on the Definition of Treatment Success
- (2011) Richard B. Aguilar CLINICAL THERAPEUTICS
- Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
- (2011) J. Dushay et al. DIABETES CARE
- Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial
- (2011) S. L. Samson et al. DIABETOLOGIA
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
- (2011) R. Kodera et al. DIABETOLOGIA
- Clinical Use of Liraglutide in Type 2 Diabetes and its Effects on Cardiovascular Risk Factors
- (2011) Ajay Varanasi et al. Endocrine Practice
- Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance
- (2011) Joan Vendrell et al. ENDOCRINOLOGY
- Emerging GLP-1 receptor agonists
- (2011) Asger Lund et al. EXPERT OPINION ON EMERGING DRUGS
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes
- (2011) Padma Sathyanarayana et al. Obesity
- GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
- (2011) Shvetank Sharma et al. PLoS One
- Human Fatty Liver Disease: Old Questions and New Insights
- (2011) J. C. Cohen et al. SCIENCE
- Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series
- (2010) Patrick R Kenny et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates
- (2010) Nicholas T. Bello et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
- (2010) Y. Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
- (2010) M. C. Bunck et al. DIABETES CARE
- Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes
- (2010) M. Lazo et al. DIABETES CARE
- Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat
- (2010) E. Sebokova et al. DIABETES OBESITY & METABOLISM
- Causes and cures for endoplasmic reticulum stress in lipotoxic β-cell dysfunction
- (2010) M. Cnop et al. DIABETES OBESITY & METABOLISM
- RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells
- (2010) Y. Hattori et al. DIABETOLOGIA
- Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients
- (2010) U. Pugazhenthi et al. DIABETOLOGIA
- From the metabolic syndrome to NAFLD or vice versa?
- (2010) Ester Vanni et al. DIGESTIVE AND LIVER DISEASE
- Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
- (2010) Jody Dushay et al. GASTROENTEROLOGY
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
- (2010) Nitika Arora Gupta et al. HEPATOLOGY
- Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
- (2010) Shani Ben-Shlomo et al. JOURNAL OF HEPATOLOGY
- Cutoff points of abdominal obesity indices in screening for non-alcoholic fatty liver disease in Asians
- (2010) Hye Jin Yoo et al. LIVER INTERNATIONAL
- Effect of Exenatide on Fat Deposition and a Metabolic Profile in Patients with Metabolic Syndrome
- (2010) Manuel González-Ortiz et al. Metabolic Syndrome and Related Disorders
- Role of the glucagon-like-peptide-1 receptor in the control of energy balance
- (2010) Matthew R. Hayes et al. PHYSIOLOGY & BEHAVIOR
- Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression
- (2009) Le Thi Kim Chung et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression
- (2009) Yuji Ishibashi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
- (2009) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
- (2009) J. Jendle et al. DIABETES OBESITY & METABOLISM
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- Advances in pediatric nonalcoholic fatty liver disease
- (2009) Rohit Loomba et al. HEPATOLOGY
- Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
- (2009) K. B. Hansen et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease
- (2009) Sehee Kim et al. JOURNAL OF ENDOCRINOLOGY
- Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension
- (2009) F. Fallo et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Inflammation and adipose tissue macrophages in lipodystrophic mice
- (2009) L. Herrero et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exendin-4 Protects -Cells From Interleukin-1 -Induced Apoptosis by Interfering With the c-Jun NH2-Terminal Kinase Pathway
- (2008) M. Ferdaoussi et al. DIABETES
- Activation of Peroxisome Proliferator-Activated Receptor / Inhibits Lipopolysaccharide-Induced Cytokine Production in Adipocytes by Lowering Nuclear Factor- B Activity via Extracellular Signal-Related Kinase 1/2
- (2008) R. Rodriguez-Calvo et al. DIABETES
- Shikonins attenuate microglial inflammatory responses by inhibition of ERK, Akt, and NF-κB: neuroprotective implications
- (2008) Kyong Nyon Nam et al. NEUROPHARMACOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started